9 Best Gene-Editing Stocks to Buy According to Hedge Funds

3. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Number of Hedge Fund Holders: 53

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the best gene-editing stocks to buy according to hedge funds. On November 10, Stifel maintained a Hold rating on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). The firm also kept its price target at $445 for the stock. Stifel’s analysts referenced Vertex’s presentation of povetacicept (a dual BAFF/APRIL inhibitor) open-label Phase 1/2 results at the American Society of Nephrology (ASN) on November 8. They highlighted strong efficacy for both IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) indications.

Separately, Vertex presented its business and strategic pipeline developments at the UBS Global Healthcare Conference 2025 on November 11. The presentation covered the company’s progress in cystic fibrosis treatments, including updates on ALYFTREK, and its efforts to expand Medicaid coverage for these therapies. Management highlighted that povetacicept received Fast Track Designation from the FDA for pMN. Vertex also outlined its research pipeline addressing other serious diseases, including neuropathic pain, type 1 diabetes, and APOL1-mediated kidney disease.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a global biotechnology company. It develops and commercializes therapies for serious diseases, with a primary focus on cystic fibrosis and genetic disorders. Its main products include Trikafta and other treatments for cystic fibrosis.